(inter)national congresses, symposia
national antibiogram committee
working party on the scientific study of travel medicine
recognition as infectiologist and medical microbiologist
interuniversity certificate in clinical infectiology and mediacl microbiology
"Interim clinical guidance for patients with suspected or confirmed COVID-19 in Belgium"
(these recommendations may be subject to modifications, this link always leads to the most recent version).
"Conflicts of interest"
of the members of the working party on "clinical guidance for adults".
"Richtlijnen voor de behandeling van kinderen met COVID-19"
[guidelines of the UZ Leuven, revised in an independent way by the Belgian COVID-19 Paedia-tric Task Force (in Dutch)].
"Recommandations pour le traitement des enfants atteints de COVID-19"
[guidelines of the UZ Leuven, revised in an independent way by the Belgian Pae-diatric Covid-19 Task Force (in French)].
Reimbursement terms and conditions (RIZIV-INAMI) of the drugs mentioned in the recommendations.
): not reimbursed in this indication.
Hydroxychloroquine sulphate (
): reimbursed in chapter I (even if, as in this case, the drug is used outside the officially registered indications).
Chloroquine phosphate (extemporaneous preparation): only reimbursed if chloroquine phosphate is the only active ingredient of the preparation.
Chloroquine base (imported in line with article article 105): not reimbursed.
Mandatory reporting forms for the admission and discharge to and from the hospital of patients with COVID-19.
Admission form: word version in Dutch
Admission form: electronic version in Dutch
Discharge form: word version in Dutch
Discharge form: electronic version in Dutch
Admission form: word version in French
Admission form: electronic version in French
Discharge form: word version word in French.
Discharge form: electronic version in French
General information concerning COVID-19/SARS-CoV-2 can be obtained from:
Federal Public Service (FPS) Health
Group of Paediatricians-Infectiologists
Federal Agency for Medicines and Health Products (FAMHP)
Centre for Pharmaceutical Information [BCFI (Dutch version)]
Centre for Pharmaceutical Information [CBIP (French version)]
European Centre for Disease Prevention and Control (ECDC)
Centers for Disease Control and Prevention (CDC)
Infectious Diseases Society of America (IDSA)
National Institutes of Health (NIH)
World Health Organization (WHO), regional office for Europe
New England Journal of Medicine (NEJM)
New England Journal of Medicine Watch (NEJM Journal Watch
"Database about all COVID-19 clinical trials running in Belgium which have been approved by FAMHP"
in the "medical condition/affection" case and click on "Apply" at the bottom of the page).
"Recycling of FFP2 masks"
[Nederlands Rijksinstituut voor Volksgezondheid en Milieu (in Dutch)].
"Pandemic preparedness plan for hospitals: part 1"
[Nederlandse Vereniging voor Intensive Care (in Dutch)].
Ethical aspects and COVID-19.
"Ethical principles concerning the proportionality of critical care during the 2020 COVID-19 pandemic in Belgium"
(Belgian Society of Intensive Care Medcine).
"Ethical aspects of making choices in the COVID-19 crisis"
[guidelines UZ Leuven (in Dutch)].
COVID-19 and HIV infection.
"SARS-CoV-2: impact on people living with HIV (PLWH)"
(guidelines Institute of Tropical Medicine, Antwerp).
"Updated EACS and BHIVA statement on risk of COVID-19 for people living with HIV (PLWH)"
"COVID-19: gastrointestinal manifestations and potential fecal-oral transmission"
(pre proof publication in "Pharmacology").
"The internet book of critical care: COVID-19"
"Chinese handbook on the prevention and treatment of COVID-19"
"Use of antiviral drugs to reduce COVID-19 transmission"
(Lancet Global Health).
Pharmaceuticals for the treatment of COVID-19.
Use of convalescent plasma.
"The feasibility of convalescent plasma therapy in severe COVID-19 patients: a pilot study"
"Investigational COVI-19 convalescent plasma: emergency innovative new drugs"
"Development initiated for a plasma-derived COVID-19 therapy"
(European Pharmaceutical Review).
"No azithromycin for the at home treatment of patients with COVID-19"
(recommendations by the Belgian health authorities BAPCOC and FAGG/ AFMPS):
"Coronavirus drugs already in the pipeline"
"Advice on the use of non-steroidal anti-inflammatories for COVID-19"
(European Medicines Agency).
"Effective treatment of severe COVID-19 patients with tocilizumab
(small Chinese trial).
"WHO to launch a multinational trial to jumpstart the search for coronavirus drugs"
(4 arms: remdesivir, lopinavir + ritonavir, lopinavir + ritonavir + inter-feron bèta, chloroquine).
"Flash VIG-news: hydroxychloroquine en chloroquine, pas op voor hun elminatie-halfwaardetijd en voor het risico op geneesmiddeleninterac-ties"
"Flash VIG-news: hydroxychloroquine en chloroquine, attention à leur demi-vie d'élimination et aux risques d'interactions médicamenteuses"
(AFMPS). Quote: "
Main conclusion: the reported adverse drug reactions of lopinavir/ritonavir, remdesivir and hydroxychloroquine are in line with their known safety profile. However, interpretation of these data must be done with some caution (considering underreporting, ...).
"Summary of adverse drug reactions in COVID-19"
"Tocilizumab safety profile"
At home treatment of adult patients with community acquired bacterial pneumonia (IGGI recommendations).
CAP subgroup I
CAP subgroup II
CAP subgroup I
CAP subgroup II
SBIMC - BVIKM